This morning, ProMetic announced it had closed a previously announced bought deal that saw the company issue 13.2-million shares at $1.90 for proceeds of $25.08-million. The deal was led by Canaccord and included RBC and Beacon Securities.
Ridgeway says the financing will give ProMetic the runway to bring its large pipeline of drugs forward. The analyst reminded that resin sales can be lumpy, and that timing is simply not under ProMetic’s control.
“With >$30M of cash on hand following the raise, management now has the resources to fully fund PBI-4050’s Phase II program and the registration trials for plasminogen, AAT, IVIG and two additional products. In addition, if PBI-4050 produces positive results in any of its planned Phase II studies, PLI should be in a stronger position to partner the asset,” said Ridgeway.
In a research update to clients this morning, Ridgeway maintained his “Buy” rating and $3.10 price target on ProMetic, implying a return of 56% at the time of publication.
On Sept. 12, Ventum Capital Markets analyst Rob Goff cut his target price for NowVertical Group (NowVertical Group Stock Quote,… [Read More]
In a Sept. 11 report, Roth Capital Markets analyst Sean McGowan raised his 12-month target price on GURU Organic Energy… [Read More]
Canadian household balance sheets remained resilient in the second quarter of 2025, with net worth edging higher despite elevated debt-servicing… [Read More]
Haywood Capital Markets analyst Neal Gilmer initiated coverage on High Tide (High Tide Stock Quote, Chart, News, Analysts, Financials TSXV:HITI)… [Read More]
TD Cowen analyst David Kwan maintained a “Buy” rating and C$7.50 target price on WELL Health Technologies (WELL Health Stock… [Read More]
Linde Equity Fund analyst Teal Linde told BNN Bloomberg’s Market Watch on Sept. 8 that Pinterest (Pinterest Stock Quote, Chart,… [Read More]